Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

By Baguley Bruce C   Siemann Dietmar W  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1413-1425

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

By Jameson Michael B   Head Michelle  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1315-1326

Informa Healthcare

Access to resources Recommend Favorite

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

By Head Michelle   Jameson Michael B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 295-304

Informa Healthcare

Access to resources Recommend Favorite

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

By Moulder Stacy   Dhillon Navneet   Ng Chaan   Hong David   Wheler Jennifer   Naing Aung   Tse Susan   La Paglia Amy   Dorr Robert   Hersh Evan   Boytim Michelle   Kurzrock Razelle  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 634-640

Springer Publishing Company

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.  

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite